Okomera’s Ocentra represents a significant innovation in organoid-based drug discovery, offering a compact, fully automated platform powered by advanced microfluidics. Unlike traditional manual methods, Ocentra simplifies and accelerates the creation and screening of organoids, requiring as few as 50 cells per organoid. The plug-and-play system integrates seamlessly into standard lab workflows, democratizing access to high-content assays previously limited to highly specialized labs. Its launch at the MPS World Summit and VivaTech underscores its readiness for global adoption.

Designed for versatility, Ocentra supports a wide range of assays—including small molecules, biologics, immune co-cultures, and CRISPR-based screenings—on both fresh and frozen biopsies. Each experiment feeds directly into Okomera AI, the company’s proprietary analysis software, providing an end-to-end solution from sample to actionable insight. This closed-loop workflow dramatically reduces hands-on time, minimizes error, and enhances reproducibility, enabling researchers to conduct robust preclinical studies with greater speed and confidence.

Ocentra’s impact extends beyond laboratory efficiency—it holds promise for advancing personalized medicine, translational research, and preclinical drug evaluation. By lowering the barrier to automated, high-throughput organoid screening, Okomera empowers academic labs, biotech startups, and pharmaceutical companies to explore complex biology with unprecedented ease. As early users begin validating its potential, Ocentra is poised to become a central engine in the next wave of precision therapeutics and functional tissue modeling.

MedTech Spectrum's Summary

Scalable Innovation: Ocentra introduces a fully automated, microfluidics-based platform that simplifies complex organoid workflows, making high-throughput drug screening more accessible and reproducible.

End-to-End Efficiency: With integrated assay capabilities and built-in AI-powered analysis, Ocentra offers a seamless, sample-to-insight solution that shortens the research timeline and enhances data quality.

Enabler of Precision Medicine: By supporting diverse assays on minimal biopsy input, Ocentra empowers researchers and clinicians to advance personalized therapies and accelerate preclinical discoveries.